Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars Payments In Medicare: CMS Signals Willingness To Change

Executive Summary

Policy of paying for all biosimilars referencing the same drug at one blended rate is under review, to the relief of product developers and other stakeholders.

You may also be interested in...



Biosimilar Coding Policy For Medicare Reversed To 'Promote Innovation'

Decision reflects Trump Administration's willingness to reconsider past efforts at cost control to address biopharma industry's concerns.

Biosimilar Coding Policy For Medicare Reversed To 'Promote Innovation'

Decision reflects Trump Administration's willingness to reconsider past efforts at cost control to address biopharma industry's concerns.

Medicare Coding Change For Biosimilars Could Save $65bn, Firms Say

Biopharma manufacturers, payers and other stakeholders strongly support changing an Obama-era policy for reimbursing biosimilars under Medicare Part B in comments to the Centers for Medicare and Medicaid Services.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS121111

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel